Today's Breaking News
- Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
- Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine
- Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg
Latest R&D and Business News
- Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE sNDA in Advanced Pancreatic Cancer
- Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
- Lightlake Therapeutics’ Binge Eating Disorder Treatment Phase II Trial Results Presented At APA 2013 Annual Meeting
- Promedior Presents Encouraging Results from Clinical Study of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis
- FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
- Nordion Enters into Agreement to Divest Targeted Therapies Business to BTG plc
- Karolinska Development AB (publ): First patient dosed in the Phase I/II study of Umecrine Mood’s candidate drug for premenstrual dysphoric disorder
- Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer
- Takeda Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients with Newly Diagnosed Multiple Myeloma
- Arsanis Nominates Preclinical Candidate for Staphylococcus aureus Program
- Lpath Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP
- Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients